Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Shattuck Labs, Inc. (STTK : NSDQ)
 
 • Company Description   
Shattuck Labs Inc. is a clinical-stage biotechnology company. It engages in development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of cancer and autoimmune disease. The company's wholly owned program includes SL-172154. It operates principally in Durham, North Carolina and Austin, Texas. Shattuck Labs Inc. is based in Austin, United States.

Number of Employees: 85

 
 • Price / Volume Information   
Yesterday's Closing Price: $2.98 Daily Weekly Monthly
20 Day Moving Average: 205,231 shares
Shares Outstanding: 42.38 (millions)
Market Capitalization: $126.29 (millions)
Beta: 2.44
52 Week High: $31.23
52 Week Low: $2.88
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -18.36% -8.05%
12 Week -42.69% -37.00%
Year To Date -64.98% -55.92%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
500 W. 5TH STREET SUITE 1200
-
AUSTIN,TX 78701
USA
ph: 512-900-4690
fax: -
investorrelations@shattucklabs.com http://www.shattucklabs.com
 
 • General Corporate Information   
Officers
Taylor Schreiber - Chief Executive Officer and Director
George Golumbeski - Chairman
Andrew R. Neill - Andrew R. Neill
Helen M. Boudreau - Director
Neil Gibson - Director

Peer Information
Shattuck Labs, Inc. (CORR.)
Shattuck Labs, Inc. (RSPI)
Shattuck Labs, Inc. (CGXP)
Shattuck Labs, Inc. (BGEN)
Shattuck Labs, Inc. (GTBP)
Shattuck Labs, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 82024L103
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/10/22
Share - Related Items
Shares Outstanding: 42.38
Most Recent Split Date: (:1)
Beta: 2.44
Market Capitalization: $126.29 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.61 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.45 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/10/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.51
Price/Cash Flow: -
Price / Sales: 13.69
EPS Growth
vs. Year Ago Period: -107.14%
vs. Previous Quarter: -422.22%
Sales Growth
vs. Year Ago Period: 2,141.28%
vs. Previous Quarter: 1,483.05%
ROE
03/31/22 - -21.79
12/31/21 - -16.23
09/30/21 - -22.61
ROA
03/31/22 - -19.17
12/31/21 - -14.17
09/30/21 - -19.64
Current Ratio
03/31/22 - 15.16
12/31/21 - 11.73
09/30/21 - 15.21
Quick Ratio
03/31/22 - 15.17
12/31/21 - 11.72
09/30/21 - 15.21
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -207.91
12/31/21 - -149.83
09/30/21 - -5,061.13
Book Value
03/31/22 - 5.87
12/31/21 - 6.43
09/30/21 - 6.20
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©